Onxeo Reports its Full-Year 2021 Financial Results and Announces Additional Financing of €12 Million

> Cash position of €17.9 million as of December 31, 2021 > Additional financing of €12 million subscribed by historical shareholders Invus and Financière de la Montagne in the form of the issuance

Related Keywords

Australia ,Japan ,United States ,Canada ,Paris ,France General ,France ,Copenhagen ,Køavn ,Denmark ,America ,French ,American ,Julien Miara ,Acrotech Biopharma ,Judith Greciet ,Emmanuel Huynh ,Arthur Rouill ,Onxeo Sa Euronext ,Robertl Coleman ,Valerie Leroy ,Gustave Roussy ,Bryan Giraudo ,Institut Curie ,Gossamer Bio Inc ,Nasdaq ,Audit Committee ,Trademark Office ,American Association For Cancer Research ,Scientific Advisory Committee ,Company Group ,Us Oncology Network ,Euronext Growth Paris ,Nasdaq First North Copenhagen ,Guaranteed Loans ,Revocan Phase ,American Association ,Cancer Research ,Annual Meeting ,Shefali Agarwal ,Chief Scientific Officer ,Jacques Mallet ,Senior Vice President ,Corporate Strategy ,Executive Leadership Team ,Gossamer Bio ,Chief Executive Officer ,Mixed General Meeting ,Invus Public Equities ,Euronext Growth ,Euronext Paris ,Nasdaq First North ,Onxeo ,Reports ,Bull ,Ear ,021 ,Financial ,Results ,Nnounces ,Dditional ,Financing ,Billion ,